European drug regulators have recommended market approval for dexamfetamine sulfate (Dexamed, Kohne Pharma) as a second-line treatment for attention-deficit/hyperactivity disorder (ADHD) in children. The drug, a 5-mg tablet, is a chemical cousin of ...
from Meta Search Alerts http://ift.tt/1ideqmV
via IFTTT
from Meta Search Alerts http://ift.tt/1ideqmV
via IFTTT
No comments:
Post a Comment